Maves (Homera Health) Review
Best for: Performance-oriented buyers (men's health + body optimization framing) seeking aggressive first-month pricing ($99/mo semaglutide intro) with a verifiable LegitScript ID, all-50-state coverage, and brand-plus-parent corporate disclosure (Maves under Homera Health). Strong fit for buyers who prioritize transparency signals (verifiable LegitScript ID + verbatim FDA disclaimer) over named pharmacy partners.
Maves (homerahealth.com — Maves is the consumer-facing brand operating under parent company Homera Health, with the login portal at app.homerahealth.com) is a performance-driven men's-health-and-body-optimization telehealth platform offering compounded semaglutide for weight loss and sermorelin for anti-aging. Compounded semaglutide starts at $99/month for the first month (one of the most aggressive intro prices in the WLR directory); sermorelin starts at $124/month. Tirzepatide also offered for weight loss (pricing not explicitly stated). All plans include 'the medical consultation, prescription medications when approved, ongoing clinical support, and free shipping' with 'no hidden or additional fees.' LegitScript Certified with verifiable ID 46200381. Verbatim FDA compounded-medication disclaimer published: 'Compounded medications are not reviewed or approved by the FDA for safety or effectiveness. A prescription is required, and individual results may vary.' Available in 'all 50 U.S. states.' Pharmacy described generically as 'licensed U.S. pharmacies' (specific 503A name/address not disclosed). Brand positioning: 'Performance-driven' emphasizing 'fat loss, lean muscle gains, optimized energy' — athletic/performance lifestyle framing rather than clinical weight management alone. Live-verified 2026-05-19.
High confidence · Last verified 2026-05-19 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Maves (Homera Health) offers the broadest state availability and easiest access.
Score Breakdown
Drugs Offered
Maves (Homera Health) prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| First-month intro | compounded | $99 |
| Sermorelin (anti-aging add-on) | compounded | $124 |
✓ Pros
- •LegitScript Certified with publicly verifiable ID (46200381) — strong trust signal beyond just the badge
- •Verbatim FDA compounded-medication disclaimer published — meets the WLR transparency standard
- •$99/mo first-month intro pricing on semaglutide is among the most aggressive in the WLR directory
- •All-50-state coverage explicitly stated (no vague 'most states' language)
- •Brand-and-parent disclosure (Maves + Homera Health) gives buyers two trace points for accountability
- •Bundled all-inclusive pricing (consult + meds + clinical support + free shipping) — no hidden fees framing matches Elara's transparency
- •Performance-driven positioning differentiates from clinical-weight-loss-only competitors and appeals to athletic-buyer segment
✗ Cons
- •Specific 503A pharmacy partner NOT named (only 'licensed U.S. pharmacies' generic framing)
- •Tirzepatide pricing NOT explicitly stated on the homepage — only listed as an offering
- •Named medical director / clinical leadership NOT disclosed
- •Refund / cancellation policy NOT publicly detailed
- •Governing law / arbitration venue / corporate physical address NOT disclosed
- •503B option NOT mentioned (503A pathway implied but not explicitly designated)
- •$99/mo is FIRST-MONTH intro — refill / standard pricing not disclosed on homepage; common DTC pattern is step-up at refill
- •Men's-health positioning may not align with female-buyer segment despite the platform being available to all patients
Ready to start with Maves (Homera Health)?
Starting at $99/month. See current pricing and start your free consultation.
Sources & methodology
Our Maves (Homera Health) review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Maves (Homera Health)
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Maves (Homera Health)?
Starting at $99/month. See current pricing and start your free consultation.